Merry Christmas Quotes

Stem Cell Product Research for Life Extension

Stem Cell Product Research

Funding Aging Research

Stem Cell Products

posted on December 1, 2008

If you donated to Maximum Life Foundation, you still have some premiums coming your way, specifically stem cell signals cosmetics and super peptide nutraceuticals. (This commentary is about life™s setback™s and what you can do about them.)

As you know, there were some delays. Stem Cell Products, LLC went through another when a shipment of printed packages got crushed on the way to the manufacturer. A reorder set the product the launch back by about three weeks. This was painful, since it was the most recent production delay that caused the company to miss the Holiday season. Ouch! Expensive? Yes. Irritating? Yes again. Devastating? Not at all. In the grand scheme of things, it™s only a minor setback.

When you compare that setback with the big picture, it simply delays getting spectacular products to the public. A year from now, everyone will be laughing about it while facing new challenges. In fact, that challenge may have led to a much more efficient way to manage supplies and inventory. That may save major headaches down the road. It™s all attitude.

You and I have lots to be thankful for, and we™re especially reminded of that on this Thanksgiving weekend. Do you tend to focus on the negatives while taking positives for granted? I know I do, and I know better. How can we help it? A painful hangnail, a migrane or the flu can snatch 100% of your attention, at least for a while. Crises tend to be squeaky wheels. When things go well, don™t you go on cruise control until something goes off track?

Sure you do. So do I. When I got paralyzed, I thought my life ended. But I adapted, reached a certain level of comfort, and then reacted to a series of new crises in the ensuing years, just like you. They were minor by comparison, but attention getting and distracting. The bottom lines are the œoverwhelming hassles you face today might be trivial compared to challenges you overcame in your past, and someone always has it worse.

Whether you™re now facing the biggest challenge of your life or not, I™d like you to do yourself a favor. I want you to take three minutes and 51 seconds out of your busy day to watch the following video. It puts things squarely in perspective. If you don™t come away from this video with a greater appreciation of what you have, if you™re not inspired to take full control of your health and longevity, then nothing I or anyone else will ever say will change any destructive habits you might have.

Please click on the link below right now for the most valuable four minute investment you will ever make. Sound track is optional. 
Happy belated Thanksgiving!


Glancing at Autologous Stem Cell Therapies (November 28 2008)
The provision of autologous stem cell therapies in the for-profit world continues onwards, as this press release indicates: researchers "announced nine month follow up results for the first patient treated with engineered stem cells in a clinical study of primary pulmonary hypertension. The stem cells are extracted from patients' own blood and trained to become new blood vessels. It goes against traditional theory that we should try to fix the existing pulmonary vasculature, but we are generating new blood vessels with impressive results. The clinical study is a collaborative effort amongst physicians at Regenocyte Therapeutic, a Florida-based stem cell clinic; researchers from TheraVitae, a biotechnology company in Tel Aviv, Israel; and physicians from Regenocyte's Dominican Republic division. This is the first time medical science has successfully reversed the disease process in pulmonary hypertension, a previously untreatable condition with a very grim prognosis. Using advanced engineered stem cell technology and innovative delivery methods. We've been able to harness the regenerative power of stem cells and literally replace the damaged blood vessels in the lungs of the pulmonary hypertension patients."

Uncovering Plasticity in the Adult Brain (November 28 2008)
From ScienceDaily: "Overturning a century of prevailing thought, scientists are finding that neurons in the adult brain can remodel their connections. [researchers] saw relatively large-scale changes in the length of dendrites - branched projections of nerve cells that conduct electrical stimulation to the cell body. Even more surprising was their finding that this growth was limited to specific type of cell. The majority of cortical neurons were stable, while the small fraction of locally connecting cells called interneurons underwent dynamic rearrangement. The capacity of interneurons to remodel is not predetermined by genetic lineage, but imposed by the circuitry within the layers of the cortex itself. Our findings suggest that the location of cells within the circuit and not pre-programming by genes determines their ability to remodel in the adult brain. If we can identify what aspect of this location allows growth in an otherwise stable brain, we can perhaps use it to coax growth in cells and regions that are normally unable to repair or adjust to a changing environment."

Another Way to Look at DNA Damage and Aging (November 27 2008)
It is a widely held view that accumulating stochastic nuclear DNA damage is one contributer to aging. This is debated for degenerations other than cancer, however. Here is a different way of looking at DNA damage in stem cells, connected to the immortal DNA strand (IDS) hypothesis: "Cairns noted a mathematical discrepancy between predicted human tissue cell mutation rates and human cancer incidence [and predicted] the existence of IDSs as the essential elements of a mutation-defense mechanism in [stem cells]. Several laboratories have identified IDSs in diverse mammalian [stem cells]. Past studies focused on the potential roles of IDSs as originally envisioned in [stem cell] genetic fidelity or in the maintenance of the [stem cell] phenotype. Another possible consequence of IDSs, aging, has received little attention. Herein, the potential for cumulative chemical modifications and decompositions (i.e., 'age spots') of IDSs in [stem cells] to act as a major determinant of human aging is considered. If accrued chemical alterations of IDSs prove to be essential determinants of aging, then a means to restore IDSs may yield new strategies for tissue rejuvenation."

The Metabolic Stability Theory of Aging (November 26 2008)
There are a lot of theories of aging, some very useful, many of which overlap, and many of which are overly narrow, overly general, or otherwise unhelpful. Here's one that appears to be another way of looking at damage accumulation, or perhaps reliability theory: "Individual differences in the rate of aging are determined by the efficiency with which an organism transforms resources into metabolic energy thus maintaining the homeostatic condition of its cells and tissues. This observation has been integrated with analytical studies of the metabolic process to derive the following principle: The metabolic stability of regulatory networks, that is the ability of cells to maintain stable concentrations of reactive oxygen species (ROS) and other critical metabolites is the prime determinant of life span. Our studies delineate age and tissue specific patterns of transcriptional changes which are consistent with the metabolic stability-longevity principle. This study, in addition, rejects the free radical hypothesis which postulates that the production rate of ROS, and not its stability, determines life span."

New Scientist on Sirtuins (November 26 2008)
The New Scientist (and some of the interviewed researchers) overhype an interesting discovery: "An overworked protein that causes yeast to age when it neglects one of its functions may trigger ageing in mice too.  As we get older, genes can start to be expressed in the wrong body tissues - a process that is thought to contribute to diseases like diabetes and Alzheimer's. Yeast cells [produce] a dual-function protein called Sir2 that, while being involved in DNA repair, also helps keep certain genes switched off. As yeast cells age, the protein can't do both jobs and neglects its role as a gene suppressor. Now Sinclair's team has shown that SIRT1, the mammalian version of Sir2, also begins to neglect its gene-suppressor role in mice whose DNA is damaged, and that this may contribute to ageing. The most exciting thing is that this work may unify in a single molecular pathway what we know about ageing in different organisms such as yeast and mammals It opens up the possibility of restoring youth in the elderly by re-establishing a useful pattern of gene expression." I think it will take more than restoring gene expression:  there's also the matter - more important to my mind - of repairing the damage that caused those changes in gene expression.

Bone Made To Order (November 25 2008)
From the Telegraph: "The world's first custom-made bones that can be 'grown' in a matter of hours and fit precisely into a break could be available within three years. The new bones will replace damaged or ceramic versions that are currently used in reconstructive surgery. They are made of one of the key materials in human bone, calcium phosphate, which means they will not be rejected by the body and will be completely absorbed into the skeleton within a couple of years. We have just completed the investigative study and clinical trials are under way on patients. Some people have congenital defects, others have lost bone after undergoing surgery for cancer, while others have been in traffic accidents. The reactions we have had so far have been very favorable." Early days yet, along with flaws and limitations to the process, but this sort of medical engineering will improve just as rapidly as other biotechnology.

Steady Progress in Regenerative Medicine (November 25 2008)
Advances of the sort noted here at EurekAlert! are becoming commonplace: researchers "have been able to effectively repair damaged heart muscle in an animal model using a novel population of stem cells they discovered that is derived from human skeletal muscle tissue. These transplanted [cells] repaired the injured muscle, stimulated the growth of new blood vessels in the heart and reduced scar tissue from the injury, thereby dramatically improving the function of the injured left ventricle. This study confirms our belief that this novel population of stem cells discovered in our laboratory holds tremendous promise for the future of regenerative medicine. Specifically, myoendothelial cells show potential as a therapy for people who have suffered a myocardial infarction. The important benefit of our approach is that as a therapy, it would be an autologous transplant. This means that for a patient who suffers a heart attack, we would take a muscle biopsy from his or her muscle, isolate and purify the myoendothelial cells, and re-inject them into the injured heart muscle, thereby avoiding any risk of rejection by introducing foreign cells."

A View of Veterinary Regenerative Medicine (November 24 2008)
Regenerative medicine for animals is more advanced than that available for humans, as regulation is less oppressive. Here, a view of regenerative medicine for horses: "Tendon and ligament injuries in performance horses are the most common disorders currently being treated with stem cells in clinical trials. One researcher has shown a lower recurrence rate of bowed tendons in racehorses treated with stem cells.  Clinical trials with local stem cell injection are also being performed for treatment of suspensory ligament injuries of the fore and hind limbs. Degenerative joint disease is a problem in performance horses and has great economic impact on the equine industry. Although there are many therapies to support joint health, the majority of these treatments are to relieve the symptoms at best. Stem cell therapy for joint disease is supported by original research performed in goats. It was shown [that] joints treated with stem cells had less arthritic changes compared with nontreated joints in the same animal. Several horses have been experimentally treated for joint injuries [using] stem cell therapy and the initial results have been positive."

NOTE:  This is not only being done in clinical trials. VetStem in San Diego routinely treats horses and pets.

Wired on Longevity Drugs (November 24 2008)

From Wired: "Resveratrol has proven safe in animals and early clinical trials, but much more testing is required. As a cautionary, Longo offered the example of his own research on caloric restriction and genetic manipulation of IGF-1, a cell-growth-regulating gene. In simple organisms, it's produced the most-dramatic life extension ever seen - yeast lived 10 times its normal lifespan - but a group of Ecuadorians who naturally have that mutation have severe growth deficits and other health problems. Even Longo, however, thinks resveratrol will enjoy some success in the near future, and mitochondrial approaches are being steadily embraced within the medical research community, which has been largely frustrated in its disease-by-disease, gene-centered approach. The approach we've taken is to go one disease at a time. We've created national institutes to go after all these major diseases, and every time we identify a new gene, or do something that lets us attack disease a little more efficiently than before, everyone jumps up and says we've succeeded and that's wonderful. Such research is important, said Olshansky, but not as promising as hitting diseases at a common root. And though he won't yet commit to resveratrol as a wonder drug, he suspects that mitochondria-targeting drugs will provide a breakthrough."

Back to Top